Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Boston Scientific raises FY 2014 EPS outlook, narrows revenue outlook to a range in line with analysts' estimates; gives Q3 2014 outlook, EPS below analysts' estimates


Thursday, 24 Jul 2014 07:05am EDT 

Boston Scientific Corp:Now expects FY 2014 revenue to be in a range of $7.325 to $7.425 billion (compared to prior guidance of $7.300 to $7.500 billion), which represents growth in a range of 3 to 4 pct on a reported basis and 3 to 5 pct on an operational basis.Now expects income on a GAAP basis in a range of $0.28 to $0.32 per share (compared to prior guidance of $0.36 to $0.41).Adjusted earnings, excluding intangible asset impairment charges, acquisition- and divestiture-, litigation-, and restructuring-related charges and credits, discrete tax items, and amortization expense, in a range of $0.79 to $0.83 per share (compared to prior guidance of $0.77 to $0.82).FY 2014 revenue of $7.393 bln and EPS of $0.80 - Thomson Reuters I/B/E/S.Expects Q3 2014 sales in a range of $1.790 to $1.840 billion.Q3 2014 earnings on a GAAP basis in a range of $0.08 to $0.10 per share.Adjusted earnings, excluding acquisition- and divestiture- and restructuring-related charges and amortization expense, are estimated in a range of $0.18 to $0.20 per share.Q3 2014 revenue of $1.825 bln and EPS of $0.19 - Thomson Reuters I/B/E/S. 

Company Quote

13.15
-0.11 -0.83%
19 Dec 2014